Tags

Type your tag names separated by a space and hit enter

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
EBioMedicine. 2022 May; 79:103993.E

Abstract

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.

Links

PMC Free PDF

Authors+Show Affiliations

Dockrell HM
Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel Street, London WCE 7HT, UK. Electronic address: hazel.dockrell@lshtm.ac.uk.
McShane H
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK.

MeSH

BCG VaccineCOVID-19COVID-19 VaccinesHumansMycobacterium bovisMycobacterium tuberculosisSARS-CoV-2Tuberculosis VaccinesVaccination

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35427852

Citation

Dockrell, Hazel M., and Helen McShane. "Tuberculosis Vaccines in the Era of Covid-19 - what Is Taking Us so Long?" EBioMedicine, vol. 79, 2022, p. 103993.
Dockrell HM, McShane H. Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? EBioMedicine. 2022;79:103993.
Dockrell, H. M., & McShane, H. (2022). Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? EBioMedicine, 79, 103993. https://doi.org/10.1016/j.ebiom.2022.103993
Dockrell HM, McShane H. Tuberculosis Vaccines in the Era of Covid-19 - what Is Taking Us so Long. EBioMedicine. 2022;79:103993. PubMed PMID: 35427852.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? AU - Dockrell,Hazel M, AU - McShane,Helen, Y1 - 2022/04/12/ PY - 2022/01/24/received PY - 2022/03/11/revised PY - 2022/03/24/accepted PY - 2022/4/16/pubmed PY - 2022/5/18/medline PY - 2022/4/15/entrez KW - SARS-CoV-2 KW - Tuberculosis KW - Vaccines SP - 103993 EP - 103993 JF - EBioMedicine JO - EBioMedicine VL - 79 N2 - The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines. SN - 2352-3964 UR - https://www.unboundmedicine.com/medline/citation/35427852/Tuberculosis_vaccines_in_the_era_of_Covid_19___what_is_taking_us_so_long DB - PRIME DP - Unbound Medicine ER -